Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized trial of tildrakizumab versus placebo and etanercept in moderate-to-severe chronic plaque psoriasis
2013-001740-54Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of tildrakizumab in psoriasis and plaque psoriasis (3 arms), sponsored by Merck & Co. Primary endpoints: PASI 75 response at Week 12, Physician's Global Assessment response at Week 12 and 2 more. Started Sep 2013; status: terminated.
02
Drugs
tildrakizumab
03
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on 2013-001740-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001740-54.